Jasper Therapeutics Presents Promising Updated Data on Briquilimab for Mast Cell-Driven Diseases at AAAAI 2025

Jasper Therapeutics, Inc. (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit ...

March 03, 2025 | Monday | News
GSK Announces Positive Phase III Results for Depemokimab in Treating Chronic Rhinosinusitis with Nasal Polyps

GSK plc announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depemokimab versus pl...

March 03, 2025 | Monday | News
Amgen and AstraZeneca's TEZSPIRE® Demonstrates Significant Efficacy in Phase 3 WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps

Amgen and AstraZeneca announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE® (tezepelumab-ekko) signi...

March 03, 2025 | Monday | News
Roche Group Unveils Promising Results from NIH-Sponsored OUtMATCH Study, Highlighting Xolair® as a Leading Treatment for Food Allergies

Roche Group announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored Phase III OUtMATCH study, which provi...

March 03, 2025 | Monday | News
CARsgen Therapeutics Initiates First Patient Dosing of KJ-C2219 in Systemic Lupus Erythematosus Trial

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,...

February 28, 2025 | Friday | News
Myriad Genetics Partners with Gabbi to Enhance Breast Cancer Risk Assessment and Specialist Care

Myriad Genetics, Inc., a leader in molecular diagnostics testing and precision medicine, announced a collaboration with Gabbi, a telehealth solution f...

February 28, 2025 | Friday | News
Alumis to Present Data on A-005, a Novel TYK2 Inhibitor, at ACTRIMS Forum 2025

Alumis Inc. (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision app...

February 28, 2025 | Friday | News
Medigene and EpimAb Partner to Advance Off-the-Shelf TCR-TCE Therapies for Cancer

Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and dev...

February 27, 2025 | Thursday | News
Inventiva's Lanifibranor Demonstrates Potential to Reduce Portal Hypertension in Preclinical Study

Inventiva ("Inventiva" or the "Company"), a clinical-focused biopharmaceutical company focused on the development of orally administered small molecules fo...

February 27, 2025 | Thursday | News
Avance Biosciences Earns CLIA Registration to Enhance Clinical Trial Support

Avance Biosciences, a leading provider of high-quality analytical and bioanalytical services for the pharmaceutical industry, is pleased to announce that i...

February 27, 2025 | Thursday | News
Polycythemia Vera A Rare Blood Disorder Affecting Thousands

Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an accompanying increase in white bloo...

February 27, 2025 | Thursday | News
ORIC Pharmaceuticals Announces Refined Registrational Plans for Lead Programs and Extended Cash Runway Into 2027

ORIC Pharmaceuticals, Inc. a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced ...

February 26, 2025 | Wednesday | News
Novita Pharmaceuticals Unveils Promising Phase 2 Results for NP-G2-044 in Combination with Anti-PD-1 Therapy at AACR IO Annual Meeting

 Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through i...

February 26, 2025 | Wednesday | News
Telix Pharmaceuticals Announces FDA Acceptance of Biologics License Application for Breakthrough Kidney Cancer Imaging Agent TLX250-CDx

Telix Pharmaceuticals Limited  announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License...

February 26, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close